UNSPSC 51351907: Norgesterone

This classification denotes a therapeutic progestin with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YFS274763Y, chemically known as 19-norpregna-5(10),20-dien-3-one, 17-hydroxy-, (17alpha)- (9ci) but generally known as norgesterone, which bears US NIH Compound Identifier 65606. European Medicines Agency schedules Norgesterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09368MIG.

UNSPSC 51351907 Norgesterone is a Commodity code that covers generic hormonal contraceptive active pharmaceutical ingredients and finished pharmaceutical products supplied through state and local cooperative purchasing vehicles. State and local governments procure norgesterone-containing formulations — including oral contraceptives, implants, injectables, and other dosage forms — primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions to achieve volume pricing and standardized supply-chain terms. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active in this space, using cooperative RFP vehicles to establish master agreements with pharmaceutical manufacturers and distributors. Vendors responding to these procurements must demonstrate cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, established relationships with authorized wholesalers (such as AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), and the ability to supply products with NDC codes, detailed product specifications, and pricing structures including flat-price, net-price, or WAC-minus formats.

MMCAP's most recent activity on norgesterone and related generics spans Minnesota and participating states including Oregon. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, titled "MMCAP Generic Multi Source Pharmaceuticals and OTC Products," with a response deadline of March 26, 2026. The RFP establishes multiple contracts for generic multi-source pharmaceuticals with awarded vendors effective July 1, 2026, through June 30, 2028, and evaluation weights pricing competitiveness at 75 percent, fixed pricing at 10 percent, administrative compliance at 5 percent, EDI capability at 5 percent, and a 3 percent administrative fee commitment at 5 percent. All products must be available in the marketplace by May 15, 2026, and vendors must maintain insurance including $5,000,000 commercial general liability per occurrence and $2,000,000 each in network security and professional liability coverage. No specific set-aside restrictions or minority business enterprise designations are disclosed in the solicitation materials.